Pediatric psoriasis in children under 6 has long forced clinicians into an uncomfortable compromise: topical steroids that work but carry well-documented risks on thin or intertriginous skin, or systemic options poorly suited to toddlers. That calculus shifted on June 29, when the FDA approved a supplemental indication for roflumilast cream 0.3% (ZORYVE) down to age 2, making it the first once-daily, steroid-free topical approved for plaque psoriasis in that age group.
The approval rests on a 4-week Maximal Usage Systemic Exposure study (ARQ-151-216) in children ages 2 to 5 with plaque psoriasis covering at least 2% body surface area, supplemented by 24 weeks of open-label safety data from extension study ARQ-151-306. Neither was a placebo-controlled efficacy trial in the traditional sense; Arcutis instead anchored the efficacy argument to the DERMIS-1 and DERMIS-2 Phase 3 trials, which evaluated the cream in patients aged 2 and older across 8-week, randomized, double-blind, vehicle-controlled designs, using IGA success (clear or almost clear, with at least a 2-grade improvement from baseline) as the primary endpoint. The FDA accepted that the safety and efficacy profiles observed in the toddler-age cohorts were consistent with those established in adolescents and adults, a regulatory extrapolation that reflects both the chronic nature of the disease and the practical difficulty of running large controlled trials in two-to-five-year-olds.
What makes this approval clinically meaningful is not just the age extension but the absence of site-specific or duration-based restrictions. Topical steroids remain guideline-unsupported for long-term use on the face, skin folds, and genitals, precisely the areas where psoriasis in young children tends to concentrate. Roflumilast cream 0.3% carries no such limitations, which closes a real prescribing gap rather than an incremental one. The drug is now the only topical PDE4 inhibitor indicated for plaque psoriasis in children under 6, and its label explicitly includes intertriginous areas. Arcutis has also layered in a prior 0.05% roflumilast cream approval for atopic dermatitis in the same 2-to-5 age band, meaning the company now holds two distinct pediatric roflumilast franchises in overlapping patient populations.
The one number worth tracking as this label expands into clinical practice is real-world PK data in the youngest patients. The MUSE study design was built to confirm systemic exposure stays within acceptable bounds under maximal-use conditions, not to generate long-term pharmacokinetic surveillance. If post-marketing data in routine care, where application may be less controlled than in a study, shows meaningful systemic accumulation in toddlers, the current label’s unrestricted-duration language will face pressure.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
